Press coverage about Exelixis (NASDAQ:EXEL) has been trending somewhat positive on Tuesday, Accern Sentiment reports. Accern identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Exelixis earned a news impact score of 0.19 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.8501596476523 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news stories that may have effected Accern Sentiment Analysis’s rankings:
- Exelixis, Ipsen report cancer drug success in late-stage study (seekingalpha.com)
- Exelixis and Ipsen Announce Phase 3 Trial Results of Cabozantinib Demonstrating Significant Overall Survival Benefit in Patients with Previously Treated Advanced Hepatocellular Carcinoma (finance.yahoo.com)
- Analyst Recommendations for Vertex Pharmaceuticals in January (finance.yahoo.com)
- Novartis (NVS) Announces Acceptance of Humira BLA by the FDA (finance.yahoo.com)
- Why Vertex Pharmaceuticals Raised Its 2017 Revenue Guidance (finance.yahoo.com)
EXEL has been the topic of several analyst reports. SunTrust Banks reiterated a “buy” rating and issued a $38.00 price target on shares of Exelixis in a research report on Thursday, December 21st. Zacks Investment Research upgraded shares of Exelixis from a “hold” rating to a “buy” rating and set a $29.00 price target on the stock in a research report on Tuesday, October 10th. Needham & Company LLC increased their price target on shares of Exelixis from $30.00 to $33.00 and gave the stock a “buy” rating in a research report on Tuesday, October 17th. Cann reiterated a “hold” rating on shares of Exelixis in a research report on Thursday, January 4th. Finally, Oppenheimer reissued a “hold” rating on shares of Exelixis in a research note on Monday, October 16th. Six investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $32.13.
Exelixis (NASDAQ:EXEL) last released its earnings results on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.08 by $0.18. The firm had revenue of $152.50 million during the quarter, compared to analyst estimates of $104.91 million. Exelixis had a net margin of 36.80% and a return on equity of 105.47%. The business’s revenue was up 145.2% on a year-over-year basis. During the same quarter last year, the business earned ($0.04) EPS. analysts anticipate that Exelixis will post 0.49 EPS for the current fiscal year.
In other Exelixis news, Director Alan M. Garber sold 15,000 shares of the firm’s stock in a transaction dated Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total transaction of $454,500.00. Following the transaction, the director now owns 64,829 shares of the company’s stock, valued at approximately $1,964,318.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 5.10% of the company’s stock.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with our FREE daily email newsletter.